The global Nuclear Medicine Market is experiencing significant growth as nuclear medicine technologies become increasingly important for disease diagnosis, imaging, and targeted therapeutic procedures. Nuclear medicine uses radioactive materials, known as radiopharmaceuticals, to help healthcare professionals detect, evaluate, and treat various medical conditions, particularly cancer and cardiovascular and neurological disorders.
According to Fortune Business Insights, the global Nuclear Medicine Market size was valued at USD 11.77 billion in 2025. The market is projected to grow from USD 13.72 billion in 2026 to USD 55.75 billion by 2034, exhibiting a CAGR of 19.15% during the forecast period. North America dominated the Nuclear Medicine Market with a 52.67% market share in 2025, supported by advanced healthcare infrastructure, increasing adoption of nuclear imaging technologies, and strong research capabilities.
The increasing prevalence of cancer, cardiovascular diseases, and neurological disorders is one of the major factors supporting the growth of the Nuclear Medicine Market. As the global burden of these diseases increases, healthcare providers require advanced diagnostic tools that can help identify diseases at earlier stages.
Nuclear medicine provides functional and molecular information that can complement conventional imaging techniques. The ability to assess biological processes within the body is increasing the importance of nuclear imaging in modern diagnostic care.
Radiopharmaceuticals play an important role in both diagnostic imaging and targeted treatment. Advances in radiopharmaceutical development are expanding the range of diseases that can be evaluated or treated using nuclear medicine.
In oncology, targeted radiopharmaceutical therapies are attracting significant attention because they can deliver radiation to specific biological targets. Continued research into new radioactive isotopes and molecular targets is expected to create additional opportunities for market expansion.
For detailed market insights : https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812
Diagnostic nuclear medicine includes radiopharmaceuticals and imaging technologies used to visualize physiological and biochemical processes. Techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are widely used in disease diagnosis and monitoring.
Growing demand for early and accurate disease detection is supporting the adoption of diagnostic nuclear medicine products.
Therapeutic nuclear medicine is gaining importance as healthcare systems increasingly explore targeted approaches for treating cancer and other conditions. Radiopharmaceutical therapy can deliver radiation directly to selected biological targets, helping distinguish it from conventional radiation approaches.
Advances in targeted therapies and isotope production are expected to contribute substantially to the future growth of this segment.
Oncology represents one of the most important application areas for nuclear medicine. Nuclear imaging can support cancer detection, staging, treatment planning, and monitoring. Meanwhile, targeted radiopharmaceutical therapies are expanding treatment possibilities for certain cancers.
The growing global incidence of cancer and increasing investments in precision medicine are expected to support continued demand.